Abbreviations {#nomen0010}
=============

PRDX2

:   Peroxiredoxin 2

ROS

:   Reactive oxygen species

*H. pylori*

:   *Helicobacter pylori*

WB

:   Western blot

qRT-PCR

:   Quantitative real-time PCR

ChIP

:   Chromatin Immunoprecipitation

CDDP

:   Cisplatin

GC

:   Gastric cancer

Redox

:   Reduction--oxidation reaction

FBS

:   fetal bovine serum

DAPI

:   4′, 6-diamidino-2-phenylindole

IHC

:   Immunohistochemistry

IF

:   Immunofluorescence

GEO

:   Gene Expression Omnibus

EGA

:   European Genome-phenome Archive

TCGA

:   The Cancer Genome Atlas

H~2~DCFDA

:   2′, 7′-dichlorodihydrofluorescein diacetate

1. Background {#sec1}
=============

Gastric cancer (GC) is the 4^th^ most common cancer and 3^rd^ leading cause of cancer-related deaths worldwide \[[@bib1],[@bib2]\]. Infection with *Helicobacter pylori (H. pylori)* is one of the most established risk factors for the development of gastric cancer \[[@bib3], [@bib4], [@bib5], [@bib6]\]. *H. pylori* infection affects approximately 4.4 billion people, defining it as one of the most common infections worldwide \[[@bib7]\]. Once infection with *H. pylori* is acquired, the gastric epithelium is the main interface of the host and the bacteria. Colonization of *H. pylori* infection in the gastric mucosa initiates chronic inflammatory response, leading to the development of gastritis that can progress in a multi-step gastric tumorigenesis cascade, known as Correa\'s cascade \[[@bib8], [@bib9], [@bib10]\]. This chronic pro-inflammatory environment is associated with an increase in the levels of reactive oxygen species (ROS), oxidative DNA damage with activation of oncogenic signaling pathways involved in gastric carcinogenesis \[[@bib8], [@bib9], [@bib10], [@bib11]\].

Peroxiredoxin 2 (PRDX2) is a typical 2-Cys antioxidant enzyme belonging to the peroxiredoxin family and plays an important role in scavenging H~2~O~2~ and ROS levels, therefore protecting cells from oxidative stress \[[@bib12]\]. Under normal physiological conditions, the levels of ROS are tightly controlled to maintain essential biological functions and normal cellular homeostasis \[[@bib13]\]. Interruption of the physiological balance between oxidation and reduction (redox) leads to excessive accumulation of ROS with accumulation of DNA damage \[[@bib14],[@bib15]\]. The expression of PRDX2 protein is quite abundant in mammalian cells and plays a critical role in keeping the redox balance and prolonging cell life span. A reduced PRDX protein is oxidized by ROS and H~2~O~2~ with the formation of oxidized PRDX, a key step in eliminating ROS levels with the thiol subunit of the cysteine residues \[[@bib12],[@bib16]\]. Among all PRDXs, PRDX2 is one of the most efficient ROS and H~2~O~2~ scavenger proteins, protecting cells from oxidative stress, as compared with other PRDX family members \[[@bib17]\]. PRDX2 could function as a suppressor or enhancer of tumorigenesis in a context- and cell-dependent manner, subject to etiological factors, cancer type, and stage of tumor progression \[[@bib16],[@bib18]\]. As a tumor suppressor, decreased expression of PRDX2 promotes the proliferation and migration in melanoma and is associated with EMT and activation of β-catenin signaling \[[@bib19]\]. On the other hand, overexpression of PRDX2 correlated with cancer progression in several malignancies, including cancers of the colon, cervix, lung and prostate \[[@bib20], [@bib21], [@bib22], [@bib23], [@bib24]\].

The role of PRDX2 in gastric cancer, as it relates to *H. pylori* infection, remains largely unknown. In this study, we investigated the expression pattern and function of PRDX2 in response to *H. pylori* infection in gastric cancer.

2. Methods {#sec2}
==========

2.1. Cell culture and reagents {#sec2.1}
------------------------------

Human gastric cancer cell lines AGS and SNU-1 were obtained from American Tissue Culture Collection (ATCC, Manassas, VA). SNU-1 was cultured in RPMI with 10% fetal bovine serum (FBS, Invitrogen Life Technologies, Carlsbad, California, USA) and 1% penicillin/streptomycin (GIBCO, Invitrogen Life Technologies). AGS cells were cultured in F12 with 10% fetal bovine serum (FBS, Invitrogen Life Technologies) and 1% penicillin/streptomycin (GIBCO, Invitrogen Life Technologies). Recombinant human TNF-α (No. 300-01A, PeproTech, New Jersey, USA) and Bay 11--7082 (No. S2913, Selleckchem, Houston, Texas, USA) were purchased.

2.2. Human samples {#sec2.2}
------------------

The de-identified human tissue samples used for qRT-PCR came from 40 gastric cancer and 40 normal gastric tissues. Samples were collected from the archives of Pathology and the National Cancer Institute Cooperative Human Tissue Network (CHTN). De-identified human tissues for immunohistochemistry were obtained from the Department of Gastric Surgery at the First Affiliated Hospital of Nanjing Medical University. Written informed consent was obtained from all patients. All tissue samples were obtained, coded, and de-identified in accordance with the Institutional Review Board-approved protocols.

2.3. *H. pylori* culture and infection {#sec2.3}
--------------------------------------

Wild-type CagA positive *H. pylori* 7.13, J166 and the rodent-adapted PMSS1 strain were a kind gift from Dr. Richard Peek, Jr. (Vanderbilt University Medical Center). Briefly, *H. pylori* strains were cultured in trypticase soy agar with 5% sheep blood (BD Biosciences, Bedford, Massachusetts, USA) for 3 days and transferred to a new agar plate \[[@bib25]\]. The strains were then cultured in Brucella broth with 10% serum and 10 μg/mL vancomycin at 37 °C and placed in an incubator with 5% CO~2~ overnight. The *H. pylori* bacteria was added over gastric cells, for a co-culture, at a multiplicity of infection of 100:1 and cells were harvested at different time points.

2.4. PRDX2 siRNA {#sec2.4}
----------------

PRDX2 siRNA was purchased from Ambion (AM51331, Thermo Fisher Scientific, Waltham, Massachusetts, USA) and Santa Cruz (sc-40832, Santa Cruz, Dallas, Texas, USA). A concentration of 40 nM of siRNA into 1x LipoJet Transfection buffer with LipoJet reagent (SL100567, SignaGen, Rockville, Maryland, USA) was prepared for transfection. The knockdown of PRDX2 was verified using Western blot analysis.

2.5. Western blot {#sec2.5}
-----------------

Proteins were extracted from cell lysates using standard methods. Proteins were separated by 10% or 12.5% running gel and stack gel electrophoresis, made of 40% acrylamide/bis solution, SDS, Tris and other components. Proteins were then transferred to the nitrocellulose membranes (Bio-rad, Hercules, California, USA), followed by blocking in 5% Bovine Fraction V (BSA, 9048-46-8, RPI (Research Products International), Mount Prospect, Illinois, USA) for 3h. After hybridization with primary antibodies at 4°C overnight, the membranes were washed and immunoblotted with secondary antibodies. Images were obtained by the Bio-Rad ChemiDoc XRS + System. Primary antibodies were as follows: PRDX2 (46855S, Cell Signaling Technology, Danvers, MA, USA), phospho--NF--κB-p65 (Ser536) (3033S, Cell Signaling Technology), NF-κB-p65 (D14E12) (8242s, Cell Signaling Technology), Phospho-Histone H2A.X (Ser139) (2577s, Cell Signaling Technology), Histone H2A.X (2595s, Cell Signaling Technology), Cleaved PARP (As214) (5625s, Cell Signaling Technology), PARP (46D11) (9532s, Cell Signaling Technology) and beta-Actin (A5441, Sigma-Aldrich, St. Louis, Missouri, USA).

2.6. Quantitative real-time PCR {#sec2.6}
-------------------------------

Total RNA was extracted from cells and tumor tissues using TRIzol reagent. Integrity and quantity were assessed using the NanoDrop 2000 (Thermo Fisher Scientific). The RNA was reverse transcripted with high capacity cDNA Reverse Transcription kit (4368814, Applied Biosystems, Foster City, California, USA). Universal SYBR Green Master kit was used for quantitative PCR with a 1:5 dilution cDNA and PCR was performed on the Bio-Rad CFX Connect Real-time System (Bio-Rad). The Primers used were as follows: human *PRDX2*-F: 5′-CGTCTCGGTGGACTCTCAGT-3′, human *PRDX2*-R: 5′-TCAGACAAGCGTCTGGTCAC -3; mouse *Prdx2*-F: 5′- CACCTGGCGTGGATCAATACC-3′, mouse *Prdx2*-R: 5′- GACCCCTGTAAGCAATGCCC -3'; human *HPRT1*-F 5′-TTGGAAAGGGTGTTTATTCCTCA -3′, human *HPRT1*-R 5′-TCCAGCAGGTCAGCAAAGAA -3'; mouse *Hprt1*-F: 5′-TATGCCGAGGATTTGGAAAA-3′, mouse *Hprt1*-R: 5′- ACAGAGGGCCACAATGTGAT-3'; *PMSS1*-F: 5′- CGTCCGGCAATAGCTGCCATAGT-3′, *PMSS1*-R: 5′- GTAGGTCCTGCTACTGAAGCCTTA-3. Experiments were performed in triplicate and the ΔΔC(t) method was adopted for analysis.

2.7. Reactive oxygen species {#sec2.7}
----------------------------

Reactive oxygen species (ROS) were detected using H~2~DCFDA (Thermo Fisher Scientific) \[[@bib26],[@bib27]\]. The H~2~DCFDA was dissolved in DMSO to achieve 1 mM as a stock concentration and diluted to 5 μM using PBS (phosphate buffered solution). After removing culture medium and washing with PBS, the cells were seeded in 24-well plates, incubated with dye at room temperature for 40 min in dark conditions. After removing the dye, cells were then covered in phenol red-free DMEM for 15 min at 37 °C in an incubator. Images were obtained with the All-in-One Fluorescence Microscope (BZ-X700) (Keyence, Itasca, IL, USA).

2.8. Luciferase reporter assay {#sec2.8}
------------------------------

To construct the PRDX2 promoter luciferase vector, we amplified three different promoter sequences of PRDX2 and inserted them into the luciferase reporter plasmid before the Kozak and luciferase sequences (P1: 1050 ------0 bp upstream of PRDX2 coding sequence, P2: 774 ------0 bp upstream of PRDX2 coding sequence, P3: 500 ------0 bp upstream of PRDX2 coding sequence), using VectorBuilder services (VectorBuilder Inc, Chicago, IL, USA). The NF-κB-p65 plasmid and the luciferase reporter plasmids were co-transfected into cells with empty vector as a control. The luciferase signal was detected using the luciferase reporter assay kit (Promega, Madison, Wisconsin, USA) and measured using BMG FLUOstar OPTIMA Microplate Reader (BMG LABTECH, Cary, North Carolina, USA).

2.9. Chromatin immunoprecipitation assay {#sec2.9}
----------------------------------------

The Magna ChIP™ A/G Chromatin Immunoprecipitation Kit (17--10085, Millipore Sigma, Burlington, Massachusetts, USA) was used for the Chromatin Immunoprecipitation (ChIP) assay \[[@bib25]\]. AGS cells cultured in 10-cm plates were fixed with 37% formaldehyde, followed by adding cell and nuclear lysis buffer. Chromatin fragments were sonicated on ice for 6 cycles (30s On and 30s Off at 40% amplitude). The shear cross-linked DNA was sonicated into 100--1000 bp for the best efficiency of pull-down. The immunoprecipitation antibody NF-kB-p65 (Ser536) (3033S, Cell Signaling Technology) and control antibody normal mouse IgG (12--371, Millipore Sigma), as well as protein A/G magnetic beads (CS204457, Millipore Sigma), were added into lysates and incubated at 4 °C overnight. Elution of the protein/DNA complexes was obtained after DNA purification using wash buffers and standard PCR. We designed three pairs of primers for potential NF-κB-p65 binding sites: *PRDX2*-1-CHIP-F: 5′- GATGGAGTCTTGCTGTGTGG -3′, *PRDX2*-1-CHIP-R: 5′- CATAGGGGAAAGGGGCAGAT -3' (Primer 1: −1083 ------ −921 bp); *PRDX2*-2-CHIP-F: 5′- CACACCTCACCGACCTCTTT -3′, *PRDX2*-2-CHIP-R: 5′- GAAGCTGTCACTCGGGGATA -3' (Primer 1: −832 ------ −594 bp); *PRDX2*-3-CHIP-F: 5′- TGCCCACACCCTCTCTTC -3′, *PRDX2*-3-CHIP-R: 5′- TTGCCCTACTTCTCCTGCTG -3' (Primer 1: −587 ------ −403 bp).

2.10. Immunofluorescence {#sec2.10}
------------------------

5000 cells were seeded in each well of an 8-chamber slide. After transfection with PRDX2 and *H. pylori* infection, the cells were fixed with 4% paraformaldehyde solution for 45 min at 4 °C. After washing cells, the cells were incubated in the permeabilization solution for 3 min on ice. Each well was blocked using 100 μl non-immune goat serum (50062Z, Thermo Fisher Scientific) for 20 min in the dark. Cells were incubated with primary antibodies overnight, followed by incubation with secondary antibodies for 1 h. Slides were sealed with the cover glass after DAPI was added. Primary antibodies that were used: 8-Oxoguanine (MAB3560, Sigma Aldrich, St. Louis, MO, USA) (1:100) and Phospho-Histone H2A.X (Ser139) (2577s, Cell Signaling Technology) (1:250). Secondary antibodies used were: Alexa Fluor 568 goat anti-mouse IgG (1:400) and Alexa Fluor 488 goat anti-rabbit IgG (1:400). Cells were analyzed and imaged using the All-in-One Fluorescence Microscope (BZ-X700) (Keyence).

2.11. Cell viability assay {#sec2.11}
--------------------------

To detect cell survival after knockdown of PRDX2, we used 5 μM cisplatin (CDDP) to treat AGS and SNU-1 cells for 48 and 72 hours. For each time point, 100 μl of CellTiter-Glo Reagent (Promega, Madison, Wisconsin, USA) was added into each well of the 24-well plates and placed on a shaker at room temperature for 10 min. Next, 50 μl of media was added into 96-well plates. All experiments were performed in triplicate. Data was then obtained using BMG FLUOstar OPTIMA Microplate Reader (BMG LABTECH, Cary, North Carolina, USA).

2.12. In vivo experiment {#sec2.12}
------------------------

All animal use protocols were approved by the Institutional Animal Care and Use committee of the University of Miami. C57BL/6 mice were purchased from Charles River Laboratories. Twenty mice were randomly assigned into control and PMSS1 groups with 10 mice per group. Mouse-adapted wild-type *H. pylori* strain PMSS1 (10^9^ CFU/mouse) was introduced using orogastric gavage. The control group included mice inoculated with Brucella broth. Mice were euthanized at one week or two weeks. Glandular gastric tissues were obtained for Western blot and qRT-PCR analysis.

2.13. Colony formation {#sec2.13}
----------------------

500 cells were seeded into 6-well plates and incubated at 37 °C and 5% CO~2~ for 2 weeks. Cells were fixed using ethanol and stained with 0.1% crystal violet. Images were obtained and colonies were counted.

2.14. Immunohistochemistry staining {#sec2.14}
-----------------------------------

Fifteen human gastric tissues and fifteen human normal adjacent tissues were included. Twelve male and three female patients (age 48 to 76) were diagnosed with gastric cancer with clinical stages from ⅠA to ⅡB. The gastric cancerous tissues were a mix of intestinal type (N = 9), diffuse type (N = 2) and mixed type (N = 4). These tissues were fixed in 4% paraformaldehyde and embedded in paraffin blocks. The tissues were embedded into paraffin as blocks for storage and cut into 5-μm-thick sections. For immunohistochemistry (IHC), 5-μm-thick sections were cut into glass slides. IHC procedure was performed following the standard protocol \[[@bib25]\]. Sections were incubated with primary antibody at 4 °C overnight and then incubated with a secondary antibody at room temperature for 1 hour. After washing the slides, chromogen was applied and images were obtained with the All-in-One Fluorescence Microscope (BZ-X700) (Keyence). The primary PRDX2 antibody (LF-MA0144, Thermo Fisher Scientific) (1:250) was used. The scores of tissues were assessed by an independent pathologist with ImageJ \[[@bib28],[@bib29]\]. The scores were automatically determined by imageJ and checked by the individual pathologist. The scores were presented as relative expression levels to adjacent non-cancerous tissues.

2.15. Statistical methods {#sec2.15}
-------------------------

Data was presented as mean ± SD in each experiment. The significant difference was considered as P \< 0.05 in each experiment. One-way analysis of variance (ANOVA) and Student\'s t-test were applied.

3. Results {#sec3}
==========

3.1. Overexpression of PRDX2 is a poor prognostic marker in gastric cancer {#sec3.1}
--------------------------------------------------------------------------

First, we detected PRDX2 protein expression levels in five gastric cancer cell lines. Western blot results indicated the protein expression level of PRDX2 was remarkably higher in MKN45, STKM2 and SUN-1 cells. Similar or lower expression of PRDX2 was observed in AGS and MKN28 cells. ([Fig. 1](#fig1){ref-type="fig"}A). To examine the PRDX2 expression levels in gastric cancer samples, qRT-PCR analysis in human gastric tissues samples demonstrated the *PRDX2* mRNA level was significantly higher in the gastric cancer sample (N = 40) compared with adjacent normal gastric tissues (N = 40) ([Fig. 1](#fig1){ref-type="fig"}B, P \< 0.05). However, we did not detect any significant correlation between PRDX2 mRNA expression level and TNM staging, possibly due to the limited number of cases. Furthermore, immunohistochemistry analysis was performed on human normal gastric (N = 15) and gastric cancer tissues (N = 15). Our data demonstrated that PRDX2 protein level is significantly higher in gastric cancer, as compared with normal gastric samples([Fig. 1](#fig1){ref-type="fig"}C, P \< 0.001). Similar to the mRNA expression results, we did not detect any significant association between PRDX2 protein expression level with histopathological or other clinical parameters, possibly because of the relative small sample size. To investigate the prognostic value of *PRDX2* expression, overall survival (OS), progression-free survival (PFS) and *PRDX2* mRNA expression levels were analyzed by KMplot (<http://kmplot.com/analysis/index.php?p=service>), downloaded from Gene Expression Omnibus (GEO), European Genome-phenome Archive (EGA) and The Cancer Genome Atlas (TCGA). The results revealed that patients with higher *PRDX2* expression demonstrated significantly worse OS and PFS (N = 876, divided by median *PRDX2* mRNA expression; [Fig. 1](#fig1){ref-type="fig"}D and E). These results indicate that *PRDX2* is overexpressed in gastric cancer. Moreover, PRDX2 expression level is associated with poor survival and could serve as a valuable prognostic factor in gastric cancer.Fig. 1**PRDX2 is overexpressed in gastric cancer, predicting prognosis**.(A) Western blot analysis of PRDX2 and β-actin in gastric cancer cell lines. (B) qRT-PCR analysis of PRDX2 mRNA expression level in 40 normal and 40 gastric cancer tissue samples. (C) Immunohistochemistry staining of PRDX2 on human adjacent non-cancerous gastric and gastric cancer tissues. Scale Bar: 50 μm. (D) Kaplan-Meier analysis of overall survival (OS) in gastric cancer patients based on PRDX2 expression level. (E) Kaplan-Meier analysis of progression-free survival (PFS) in gastric cancer patients based on PRDX2 expression level. \*\*\*, P \< 0.001.Fig. 1

3.2. PRDX2 expression is induced by *H. pylori* infection *in vitro* and *in vivo* {#sec3.2}
----------------------------------------------------------------------------------

Since *H. pylori* infection is a major risk factor of gastric cancer, we tested whether PRDX2 expression in gastric cancer cells is related to *H. pylori* infection. AGS and SNU-1 gastric cancer cells, with relatively low endogenous PRDX2 expression level, were examined to investigate whether *H. pylori* infection induces PRDX2 expression in gastric cells. Two *H. pylori* strains 7.13 or J166 were co-cultured with AGS or SNU-1 cells for 3 or 6 h. Western blot analysis demonstrated that PRDX2 and phospho--NF--κB-p65 protein expression levels were induced with both 7.13 and J166 infections (3 h and 6 h) in SNU-1 and AGS cells. The expression of CagA was tested to confirm the *H. pylori* infection in gastric cancer cells ([Fig. 2](#fig2){ref-type="fig"}A and B). Consistently, qRT-PCR results indicated that PRDX2 mRNA levels were significantly increased after both *H. pylori* strain infections for 6 h in AGS and SNU-1 cells ([Fig. 2](#fig2){ref-type="fig"}C and D). *H. pylori* infection induced both mRNA and protein expression levels of PRDX2 in gastric cancer cells. We used rodent-adapted *H. pylori* strain PMSS1 to infect the wild-type (WT) C57BL/6 mice to confirm *in vitro* data. Protein and RNA samples were acquired from broth (control) or *H. pylori* infected (PMSS1) mice stomach tissues. Western blot data showed the PRDX2 protein expression level was remarkably induced at 1--2 weeks post PMSS1 infection, compared with control group ([Fig. 2](#fig2){ref-type="fig"}E). We also observed an increase of phospho--NF--κB-p65 in gastric cells after PMSS1 infection ([Fig. 2](#fig2){ref-type="fig"}E). qRT-PCR demonstrated successful infections of PMSS1 ([Supplementary Fig. S1](#appsec1){ref-type="sec"}). We found that the protein expression of PRDX2 was significantly upregulated in tissues infected with PMSS1 for 1 or 2 weeks compared to control mice tissues. Next, qRT-PCR was performed to detect the PRDX2 mRNA level in control and PMSS1 infected mice gastric tissue samples. Our data revealed that PRDX2 mRNA level was significantly upregulated after PMSS1 infection ([Fig. 2](#fig2){ref-type="fig"}F). These results indicated that both PRDX2 mRNA and protein expression levels are induced by *H. pylori* infection in gastric cells *in vitro* and *in vivo*.Fig. 2**PRDX2 expression is induced by *H. pylor*i infections *in vitro* and *in vivo.***(A) and (B) Western blot data of CagA, PRDX2, p--NF--kB-p65, NF-kB-p65, and β-actin in AGS and SNU-1 cells infected with 7.13 (100 MOI), J166 (100 MOI) or PBS (Control) for 3 h and 6 h. (C) and (D) qRT-PCR analysis of PRDX2 mRNA expression levels in AGS and SNU-1 cells infected with 7.13 (100 MOI), J166 (100 MOI) or PBS (Control) for 6h. (E) Western blot analysis of PRDX2, p--NF--kB-p65, NF-kB-p65 and β-actin in control or PMSS1 infected mice for 1--2 weeks. (F) qRT-PCR analysis of PRDX2 mRNA expression level in control or PMSS1 infected mice 1--2 weeks. Quantification of Western blot data was performed using Image Lab software from Bio-Rad. \*, P \< 0.05, \*\*, P \< 0.01.Fig. 2

3.3. PRDX2 genetic knockdown induces reactive oxygen species (ROS) with or without *H. pylori* infection in gastric cancer cells {#sec3.3}
--------------------------------------------------------------------------------------------------------------------------------

To test the role of PRDX2 in regulating ROS levels, we performed experiments with or without *H. pylori* infection. Immunofluorescence staining of 2′, 7′-dichlorodihydrofluorescein diacetate (H~2~DCFDA), an ROS indicator in cells \[[@bib26],[@bib27]\], was performed in control or PRDX2 siRNA knockdown AGS and SNU-1 cells with or without *H. pylori* (7.13 or J166) infection (6 h). Our data indicated that PRDX2 knockdown significantly induced higher ROS levels without *H. pylori* infection, as compared with control ([Fig. 3](#fig3){ref-type="fig"}A and B, P \< 0.05). In the meantime, both 7.13 and J166 *H. pylori* infections induced high ROS levels, as expected. PRDX2 knockdown with 7.13 or J166 infection showed significantly higher ROS levels (P \< 0.05), compared with 7.13 or J166 infection alone in AGS or SNU-1 cells ([Fig. 3](#fig3){ref-type="fig"}A and B, P \< 0.05). PRDX2 knockdown was confirmed using Western blot analysis ([Fig. 3](#fig3){ref-type="fig"}A and B right panels). These results indicated that knockdown of PRDX2 promoted a significant increase in ROS levels, especially noted with *H. pylori* infection, in gastric cancer cells.Fig. 3**Knockdown of PRDX2 enhances *H. pylori*-induced ROS level**.(A) Left panel: the level of reactive oxygen species (ROS) was detected using H~2~DCFDA in control or PRDX2 siRNA knockdown AGS cells with or without *H. pylori* (7.13 or J166) infection for 6 h. Right upper panel: Western blot confirmed the knockdown of PRDX2 was efficient in AGS cells. Right lower panel: quantification data for A. (B), similar experiment in SUN-1 cells as in A. \*, P \< 0.05, \*\*, P \< 0.01, \*\*\*, P \< 0.001.Fig. 3

3.4. PRDX2 abrogates *H. pylori*-induced DNA damage in gastric cancer cells {#sec3.4}
---------------------------------------------------------------------------

We investigated the role of PRDX2 in protecting gastric cancer cells from *H. pylori* induced oxidative stress. By using the same experiment settings as in [Fig. 3](#fig3){ref-type="fig"}, we measured DNA lesions with 8-Oxoguanine immunofluorescence staining. Immunostaining for 8-Oxoguanine demonstrated a significant increase in oxidative DNA damage in conditions of knockdown of PRDX2, most notable with *H. pylori* infection (P \< 0.001) ([Supplementary Fig. S2](#appsec1){ref-type="sec"}). PRDX2 knockdown was confirmed using Western blot analysis ([Supplementary Fig. S2](#appsec1){ref-type="sec"} right panels). These results indicated that PRDX2 protected gastric cancer cells from oxidative DNA damage induced by *H. pylori* infection.

Because the occurrence of double-strand DNA breaks (DSB) is a natural progression of oxidative DNA damage lesions, if not repaired, we determined the levels of DSB in response to *H. pylori* and PRDX2 knockdown. p-H2A.X immunofluorescence staining in AGS or SNU-1 cells with or without *H. pylori* infection demonstrated a significant increase in DSB, following *H. pylori* infection and knockdown of PRDX2, as compared with controls (P \< 0.01) ([Fig. 4](#fig4){ref-type="fig"}A and B, P \< 0.01). Western blot analysis from these cells confirmed the increase in p-H2A.X protein expression levels after knockdown of PRDX2 ([Fig. 4](#fig4){ref-type="fig"}C & D) and similar results were found after treating cells with PRDX2 siRNA-2 ([Supplementary Fig. S3](#appsec1){ref-type="sec"}). These data demonstrated that PRDX2 protects against the formation of double-strand DNA breaks in gastric cells.Fig. 4**Knockdown of PRDX2 increases the expression of p-H2A.X with or without *H. pylori* infection**.The immunofluorescence staining of p-H2A.X in control or PRDX2 siRNA knockdown AGS cells with or without *H. pylori* (7.13 or J166) infection for 6 h. Right upper panel: Western blot confirmed the knockdown of PRDX2 was efficient in AGS cells. Right lower panel: quantification data for A. (B), similar experiment in SUN-1 cells as in A. \*, P \< 0.05, \*\*, P \< 0.01, \*\*\*, P \< 0.001. (C) Western blot analysis of CagA, PRDX2, p--NF--kB-p65, NF-kB-p65, p-H2A.X, H2A.X and β-actin in control or PRDX2 siRNA knockdown AGS cells with or without *H. pylori* (7.13 or J166) infection for 6 h. (D), similar result in SNU-1 cells as C. \*\*, P \< 0.01, \*\*\*, P \< 0.001.Fig. 4

3.5. PRDX2 expression level is regulated by NF-κB signaling in gastric cancer cells {#sec3.5}
-----------------------------------------------------------------------------------

Several studies showed that *H. pylori* infection activates NF-κB signaling in gastric cancer cells \[[@bib25],[@bib30]\]. Therefore, we investigated our hypothesis that NF-κB activation may promote PRDX2 expression to re-balance the oxidative stress and DNA damage induced by *H. pylori* infection. Western blot data demonstrated that NF-κB inhibitor Bay-11-7082 (Bay) treatment dramatically decreased the level of phospho--NF--κB-p65 and PRDX2. Meanwhile, *H. pylori* infection (7.13 or J166) induced NF-κB-p65 ([Supplementary Fig. S4](#appsec1){ref-type="sec"} A & B). Interestingly, Bay treatment abrogated the expression of PRDX2 induced by two *H. pylori* strains, indicating that *H. pylori*-induced PRDX2 expression is mediated by NF-κB signaling ([Supplementary Fig. S4](#appsec1){ref-type="sec"} A & B). To confirm our findings that PRDX2 expression was regulated by NF-κB pathway, we stimulated AGS and SNU-1  cells with TNF-α. Western blot data indicated that PRDX2 expression was induced after TNF-α treatment, as compared to control, suggesting that the NF-κB pathway played an important role in PRDX2 expression ([Supplementary Figs. S4C and D](#appsec1){ref-type="sec"}). Next, to investigate if PRDX2 is a transcription target of NF-κB signaling in gastric cells, we used luciferase reporter assay containing predicted NF-κB binding sites on PRDX2 promoter. We analyzed 0--2000 bp upstream regions of PRDX2 transcription start site. Three promoter prediction websites were used to locate the putative NF-κB binding sites within the 2000 bp PRDX2 promoter region, including Promo (<http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3>), TFbinding (<http://tfbind.hgc.jp>) and Jaspar (<http://jaspar.genereg.net>). We found 12 predicted binding sites for NF-κB on PRDX2 promoter ([Supplementary Fig. S4E](#appsec1){ref-type="sec"}). According to predictions, most predicted sites were located between the −1000 bp and +1bp of the promoter sequence. We designed three pGL3-based luciferase reporter constructs (P1--P3) of PRDX2 promoter regions containing potential binding areas (cluster A-C) ([Fig. 5](#fig5){ref-type="fig"}A). The luciferase reporter assay data revealed that NF-κB-p65 overexpression in AGS cells significantly increased PRDX2-P1 luciferase reporter activity, compared with empty vector control ([Fig. 5](#fig5){ref-type="fig"}B, P \< 0.001). Of note, we did not detect increased luciferase reporter activity of P2 or P3, following similar conditions ([Fig. 5](#fig5){ref-type="fig"}B). Because our data demonstrated that the exogenous NF-κB-p65 could increase the luciferase activity, we confirmed these results using TNF-α to activate or Bay-11-7082 to inhibit NF-κB signaling. Our results indicated that TNF-α treatment significantly increased luciferase activity of cells transfected with PRDX2-P1 reporter, rather than P2 and P3 ([Fig. 5](#fig5){ref-type="fig"}C, P \< 0.001). On the other hand, Bay-11-7082 treatment significantly decreased the luciferase activity in PRDX2-P1 reporter, but not P2 or P3 ([Fig. 5](#fig5){ref-type="fig"}C, P \< 0.05). Next, we examined PRDX2-P1 reporter activity, following *H. pylori* infection. Our data demonstrated that *H. pylori* infection (7.13 and J166) induced significant increase of PRDX2-P1 reporter activity compared with control cells ([Fig. 5](#fig5){ref-type="fig"}D, P \< 0.05). These results strongly suggest the presence of functional NF-κB binding sites on PRDX2 promoter, localized in cluster A of PRDX2-P1, that play an active role in gastric cells.Fig. 5**NF-κB-p65 binds directly to PRDX2 promoter region**.(A), Schematic diagram shows three luciferase reporters cover different DNA sequences of PRDX2 promoter region. Primers for ChiP assay are marked using 3 pairs of blue arrows. (B) Luciferase reporter assay analysis of three PRDX2 promoter luciferase reporters in AGS cells transfected with NF-kB-p65 or pcDNA. (C) Luciferase reporter assay analysis of three PRDX2 promoter luciferase reporters in AGS cells treated with 5 μM TNF-α (3 h), Bay-11-7082 11--7082 (6 h) before luciferase detection. (D) Luciferase reporter assay analysis of P1 in AGS cells infected with 100 MOI *H. pylori* for 3 h. (E) RT-PCR was performed in AGS cells after pull down NF-kB-p65 using three pairs of Primers to investigate the potential NF-kB-p65 binding sites in PRDX2 promoter region. (F) qRT-PCR analysis of DNA pulled down in E. \*, P \< 0.05, \*\*, P \< 0.01, \*\*\*, P \< 0.001. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 5

3.6. NF-kB-p65 binds to *PRDX2* gene promoter region {#sec3.6}
----------------------------------------------------

To further probe the direct NF-κB-p65 binding site to the PRDX2 promoter region within the natural chromatin context of gastric cancer cells, we designed three pairs of primers to detect the binding using chromatin immunoprecipitation (ChIP) assay. The amplification regions of the primers are shown in [Fig. 5](#fig5){ref-type="fig"}A and the nucleotide sequence of primers were shown in the methods section. Primer 1 contains the first predicted NF-κB-p65 binding site in cluster A mentioned in [Fig. 5](#fig5){ref-type="fig"}A. The second predicted NF-κB-p65 binding site in cluster A is included in the amplification sequence of Primer 2 along with all predicted binding sites of cluster B. Primer 3 targeted two predicted NF-κB binding sites in cluster C to confirm our findings of [Fig. 5](#fig5){ref-type="fig"}B to C. The DNA pull down by beads containing NF-κB-p65 antibody was utilized as a template in the RT-PCR reaction using the primers mentioned above. RT-PCR results revealed amplification of the pull downed DNA region using Primer 1 was significantly higher compared with Primer 2 or 3 ([Fig. 5](#fig5){ref-type="fig"}E and F, P \< 0.01). Because *H. pylori* 7.13 strain induced higher expression of PRDX2 at 6 h ([Fig. 2](#fig2){ref-type="fig"}C &D), we performed ChIP assay in AGS with or without infection using this strain to test whether *H. pylori* infection regulates the binding of NF-κB-p65 to PRDX2 promoter region. RT-PCR results showed that binding of NF-κB-p65 to the PRDX2 promoter region was stronger with 7.13 infection for 6 h compared with control cells, indicating that the *H. pylori* infection promotes the binding of NF-κB-p65 to the PRDX2 promoter region amplified by Primer 1, rather than Primer 2 or 3 ([Fig. 5](#fig5){ref-type="fig"}E and F, P \< 0.01). We also performed quantitative ChIP analysis using qRT-PCR from the same settings in [Fig. 5](#fig5){ref-type="fig"}E. Our data indicated that the pull downed DNA amplification with Primer 1 after *H. pylori* infection is significantly higher than without *H. pylori* infection (P \< 0.01) ([Fig. 5](#fig5){ref-type="fig"}F). We did not detect induction or significant difference in the amplification products of Primers 2 or 3, with or without *H. pylori* infection, consistent with [Fig. 5](#fig5){ref-type="fig"}E. Overall, our data indicated that PRDX2 is regulated by transcriptional factor NF-κB-p65. Our data, for the first time, reveals that there are active NF-κB-p65 direct binding sites on the PRDX2 promoter region.

3.7. PRDX2 promotes cisplatin resistance in gastric cancer cells {#sec3.7}
----------------------------------------------------------------

Our analysis of public databases demonstrated poor survival in patients with high levels of PRDX2. cisplatin (CDDP) treatment is a chemotherapeutic drug frequently used in the standard care of gastric cancer patients. We also found that PRDX2 protected gastric cancer cells from oxidative stress and DNA damage. Therefore, we postulated that PRDX2 may play a role in resistance to CDDP. Our results demonstrated that cell viability decreased significantly after knockdown of PRDX2, as compared with control ([Fig. 6](#fig6){ref-type="fig"}A and B, P \< 0.05). CDDP treatment significantly diminished cell viability in cells with knockdown of PRDX2 ([Fig. 6](#fig6){ref-type="fig"}A and B, P \< 0.05). The expression of cleaved PARP was strongly induced after knockdown of PRDX2 compared to control with or without CDDP treatment, indicating that knockdown of PRDX2 promotes cell apoptosis independently or induced by CDDP. The expression of p-H2A.X was also increased, similar to cleaved-PARP ([Fig. 6](#fig6){ref-type="fig"}C and D). Similar WB results were found after we transfected the other siRNA into cells with or without CDDP treatment and extracted proteins ([Supplementary Figs. S5A and S5B](#appsec1){ref-type="sec"}). Next, we performed CellTiter-Glo assay in cells treated with control or PRDX2 siRNA. Results indicated that PRDX2 knockdown sensitized AGS and SNU-1 cells to CDDP treatment. The IC50 of CDDP in AGS cells decreased from 2.591 μM (Control) to 1.588 μM with PRDX2 siRNA knockdown. A Similar observation was obtained in SNU-1 cells ([Fig. 6](#fig6){ref-type="fig"}E and F). Colony formation assay confirmed the IC50 findings and demonstrated significantly less colonies following PRDX2 knockdown, as compared with control cells. Collectively, our results indicated a critical cell-protective role of PRDX2, suggesting a possible role of PRDX2 in promoting cisplatin resistance in gastric cancer cells.Fig. 6**Knockdown of PRDX2 sensitized GC cells to Cisplatin treatments**.(A) and (B) ATP-Glo cell viability assay in AGS or SNU-1 cells with control or PRDX2 siRNA knockdown with or without CDDP treatment. (C) and (D) Western blot analysis of PARP, cleaved-PARP, PRDX2, P--H2A.X, H2A.X and β-actin in AGS or SNU-1 cells as in A and B. (E) and (F) CDDP IC50 was calculated in AGS and SNU-1 cells. (G) and (H) The clonogenic formation was performed in AGS and SNU-1 control or PRDX2 siRNA knockdown cells. A total of 500 cells were seeded in each well in a 6-well plate. \*, P \< 0.05, \*\*, P \< 0.01, \*\*\*, P \< 0.001.Fig. 6

4. Discussion {#sec4}
=============

Gastric cancer is the third most common cause of cancer-related deaths \[[@bib1],[@bib2],[@bib31]\]. Our study demonstrated poor clinical outcome for patients with high levels of PRDX2. Recent studies showed that PRDX2 was involved in scavenging H~2~O~2~ with important cellular physiological functions, including cell growth, differentiation, and survival \[[@bib16],[@bib32]\]. *H. pylori* is the main risk factor for gastric cancer, affecting 4.4 billion people world-wide \[[@bib3], [@bib4], [@bib5], [@bib6], [@bib7]\]. Several earlier studies have shown that *H. pylori* infection increases the levels of reactive oxygen species, oxidative stress. and DNA damage \[[@bib7],[@bib8]\]. However, accumulation of uncontrolled levels of DNA damage is lethal and not compatible with physiological cellular functions and viability \[[@bib13], [@bib14], [@bib15]\]. In this context, gastric cells must develop protective mechanisms to counteract *H. pylori*-induced oxidative damage. We discovered that PRDX2 overexpression in gastric cancer cells is induced by *H. pylori* infection. We have shown that *H. pylori*-mediated induction of PRDX2, *in vitro* and *in vivo*, protected gastric cells from *H. pylori*-induced oxidative stress and DNA damage; a step that could be critical for survival of gastric cells in response to *H. pylori* infection.

*H. pylori* infection is known to create a pro-inflammatory environment with activation of NF-ĸB signaling that also promotes gastric tumorigenesis. Activation of NF-ĸB by *H. pylori* infection induces expression of several cytokines/chemokines, growth factors, anti-apoptotic factors, angiogenesis regulators and metalloproteinases to promote gastric carcinogenesis \[[@bib25],[@bib33],[@bib34]\]. Our results indicated that *H. pylori* induced PRDX2 at mRNA levels and this expression was dependent on the activation of NF-ĸB signaling in gastric cancer cells. Bioinformatics analysis predicted multiple potential binding sites of NF-ĸB on PRDX2 promoter. We have taken a systematic approach to analyzing these potential binding sites. Our results indicated that PRDX2 promoter contains NF-ĸB binding sites, responsive to *H. pylori-* and TNFα-mediated activation of NF-ĸB. In fact, ChIP assay confirmed the luciferase reporter findings, demonstrating the presence of novel NF-ĸB binding sites on the PRDX2 promoter. However, we can not exclude the presence of other regulatory mechanisms that mediate PRDX2 induction. PRDX2 is also a direct target of HIF and its expression is induced by prolonged hypoxia in hypoxic HeLa cells \[[@bib35]\]. PRDX2 overexpression in colorectal cancer is regulated by miR-200b-3p \[[@bib36]\]. Although, we have not examined this regulatory mechanism in the context of *H. pylor*i and inflammation, we demonstrated a novel regulatory mechanism mediating PRDX2 expression in gastric cells, highly relevant to *H. pylori* infection and inflammation, the main risk factors for gastric cancer.

Chemotherapeutic regimens containing platinum analogs, such as cisplatin, remain a standard therapeutic approach in the treatment of gastric cancer. Treatment with cisplatin induces high levels of reactive oxygen species and DNA damage that mediate cancer cell death \[[@bib37],[@bib38]\]. We, therefore, investigated the role of PRDX2 in cisplatin resistance in gastric cancer. Our data indicated that PRDX2 protected against cisplatin-induced cell death. PRDX2 could have functions not limited to its antioxidant capacity. Lv et al. recently reported that PRDX2 is associated with colorectal cancer invasion, metastasis and chemotherapeutic resistance \[[@bib36]\]. In addition, PRDX2 expression is positively correlated with activation of AKT in colon cancer cells, promoting cancer cell resistance to 5-Fluorouracil treatment \[[@bib21]\]. Our results can partially explain the observed correlation between high levels of PRDX2 with poor clinical outcome. In this context, PRDX2 may be a key player of chemo/radio resistance in gastric cancer.

In conclusion, we discovered that PRDX2 is induced by *H. pylori* infection, protecting gastric cells from ROS, oxidative DNA damage, and DNA double-strand breaks. We detected and validated PRDX2 as a novel transcription target of NF-kB in gastric cancer. A high level of PRDX2 is a poor prognostic marker in gastric cancer associated with resistance to cisplatin. The future development of therapeutic strategies that target PRDX2 may be useful in the treatment of gastric cancer.
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